Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sophia GeneticsSOPH -0.33%65 Debt-to-Equity is 0.74 as of Jun. 2026, which is 517% above its 10-year median of 0.12. GuruFocus rates SOPH with a GF Score™ of 65/100 and a GF Value™ of $5.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 558 Healthcare Providers & Services companies, Sophia Genetics ranks worse than 65.23% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sophia Genetics's Debt-to-Equity or its related term are showing as below:
SOPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.12 Max: 1.37
Current: 0.74
During the past 8 years, the highest Debt-to-Equity Ratio of Sophia Genetics was 1.37. The lowest was 0.05. And the median was 0.12.
SOPH's Debt-to-Equity is ranked worse than 65.23% of 558
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs SOPH: 0.74
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sophia Genetics Debt-to-Equity Related Terms
Sophia Genetics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Debt-to-Equity of 0.74 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sophia Genetics and its competitors. This is 517% above median its historical median of 0.12. Over the past decade, Sophia Genetics' Debt-to-Equity has ranged from 0.05 to 1.37. According to the industry distribution chart, Sophia Genetics ranks #364 out of 558 companies in the Healthcare Providers & Services industry, placing it in the top 65.2%.
Is Sophia Genetics' Debt-to-Equity too high?
Sophia Genetics' current Debt-to-Equity of 0.74 is 517% above median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 1.37. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Sophia Genetics' value of 0.74 is 76.2% above this industry median. Based on the distribution chart, Sophia Genetics ranks #364 out of 558 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Debt-to-Equity compare to EVH and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #364 out of 558 companies for Debt-to-Equity. This places Sophia Genetics in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Sophia Genetics' value of 0.74 is 76.2% above this benchmark. Historically, Sophia Genetics' own Debt-to-Equity has ranged from 0.05 to 1.37 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 0.42, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Debt-to-Equity of 0.74 is 76.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Debt-to-Equity is 0.74, which is 517% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.10, compared to a current price of $7.56 — trading 48.2% above its estimated fair value. The current Debt-to-Equity is 0.74, which is 517% above median its 10-year median of 0.12 and 76.2% above the Healthcare Providers & Services industry median of 0.42. Sophia Genetics' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Debt-to-Equity is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $7.56 is trading 48.2% above its estimated GF Value™ of $5.10.
GuruFocus considers Sophia Genetics to be Significantly Overvalued.
Key valuation signals for SOPH:
Debt-to-Equity: 0.74 (517% above median its 10-year median of 0.12)
GF Value™: $5.10 vs. price of $7.56 (48.2% above fair value)
Industry Position: 76.2% above the Healthcare Providers & Services median (#364 of 558)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
65GF Score
Get the complete analysis for SOPH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
